Bank of New York Mellon’s Altimmune ALT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.1M Buy
689,713
+276,210
+67% +$825K ﹤0.01% 2923
2026
Q1
$1.27M Buy
413,503
+59,302
+17% +$252K ﹤0.01% 3064
2025
Q4
$1.28M Buy
354,201
+12,216
+4% +$53.3K ﹤0.01% 3094
2025
Q3
$1.29M Buy
341,985
+9,969
+3% +$38.5K ﹤0.01% 3058
2025
Q2
$1.28M Buy
332,016
+143,016
+76% +$774K ﹤0.01% 2983
2025
Q1
$945K Buy
189,000
+2,162
+1% +$13.7K ﹤0.01% 3101
2024
Q4
$1.35M Sell
186,838
-1,777
-0.9% -$13.6K ﹤0.01% 2962
2024
Q3
$1.16M Sell
188,615
-55,193
-23% -$374K ﹤0.01% 3058
2024
Q2
$1.62M Buy
243,808
+54,154
+29% +$400K ﹤0.01% 2913
2024
Q1
$1.93M Sell
189,654
-1,934
-1% -$19.7K ﹤0.01% 2777
2023
Q4
$2.16M Buy
191,588
+12,681
+7% +$52.9K ﹤0.01% 2793
2023
Q3
$465K Sell
178,907
-15,216
-8% -$43.7K ﹤0.01% 3583
2023
Q2
$685K Buy
194,123
+135,169
+229% +$607K ﹤0.01% 3427
2023
Q1
$249K Buy
58,954
+5,662
+11% +$67.3K ﹤0.01% 3825
2022
Q4
$877K Sell
53,292
-19,804
-27% -$222K ﹤0.01% 3256
2022
Q3
$934K Buy
73,096
+24,051
+49% +$355K ﹤0.01% 3239
2022
Q2
$574K Sell
49,045
-148,202
-75% -$914K ﹤0.01% 3508
2022
Q1
$1.2M Sell
197,247
-2,949
-1% -$21.7K ﹤0.01% 3201
2021
Q4
$1.83M Buy
200,196
+39,013
+24% +$415K ﹤0.01% 3042
2021
Q3
$1.82M Buy
161,183
+26,332
+20% +$320K ﹤0.01% 3038
2021
Q2
$1.33M Buy
134,851
+79,494
+144% +$1.09M ﹤0.01% 3243
2021
Q1
$782K Sell
55,357
-4,638
-8% -$75K ﹤0.01% 3472
2020
Q4
$677K Buy
59,995
+5,448
+10% +$64.2K ﹤0.01% 3467
2020
Q3
$720K Buy
54,547
+12,137
+29% +$243K ﹤0.01% 3307
2020
Q2
$454K Hold
42,410
﹤0.01% 3530
2020
Q1
$136K Sell
42,410
-33,842
-44% -$77.8K ﹤0.01% 3823
2019
Q4
$144K Hold
76,252
﹤0.01% 3973
2019
Q3
$149K Buy
76,252
+43,013
+129% +$95.3K ﹤0.01% 3967
2019
Q2
$79K Buy
+33,239
New +$88.9K ﹤0.01% 4067
2018
Q3
Sell
-2,211
Closed -$30K 4241
2018
Q2
$30K Buy
+2,211
New +$43.5K ﹤0.01% 4144
2018
Q1
Sell
-2,297
Closed -$137K 4312
2017
Q4
$137K Buy
+2,297
New +$147K ﹤0.01% 4023
2017
Q2
Sell
-610
Closed -$149K 4293
2017
Q1
$149K Hold
610
﹤0.01% 3946
2016
Q4
$594K Buy
610
+62
+11% +$55.5K ﹤0.01% 3510
2016
Q3
$477K Sell
548
-29
-5% -$22.7K ﹤0.01% 3565
2016
Q2
$423K Buy
577
+392
+212% +$268K ﹤0.01% 3608
2016
Q1
$105K Buy
185
+11
+6% +$5.63K ﹤0.01% 3951
2015
Q4
$99K Hold
174
﹤0.01% 4067
2015
Q3
$69K Hold
174
﹤0.01% 4198
2015
Q2
$94K Buy
174
+33
+23% +$16.7K ﹤0.01% 4057
2015
Q1
$69K Hold
141
﹤0.01% 4109
2014
Q4
$76K Hold
141
﹤0.01% 4103
2014
Q3
$75K Hold
141
﹤0.01% 4114
2014
Q2
$60K Buy
141
+1
+0.7% +$452 ﹤0.01% 4060
2014
Q1
$77K Hold
140
﹤0.01% 4029
2013
Q4
$78K Sell
140
-4
-3% -$2.39K ﹤0.01% 4062
2013
Q3
$91K Buy
144
+4
+3% +$2.29K ﹤0.01% 3973
2013
Q2
$67K Buy
+140
New +$69.4K ﹤0.01% 4000

Other funds holding ALT

Bank of New York Mellon's ALT Position: Q2 2026 in Review

Bank of New York Mellon increased its Altimmune (ALT) stake by 67% in Q2 2026, buying an estimated $825K and bringing the position to 689,713 shares worth $2.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2923.

Bank of New York Mellon first reported a position in ALT in Q2 2013 and has held it in 47 quarters since. The position peaked at $2.16M in Q4 2023. 85 funds tracked by Wall St. Rank hold ALT as of Q2 2026.

  • Bank of New York Mellon held 689,713 shares of Altimmune worth $2.1M as of Q2 2026.
  • Bank of New York Mellon bought 276,210 Altimmune shares in Q2 2026, an estimated $825K.
  • Altimmune made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2923 holding.
  • Bank of New York Mellon first reported a position in Altimmune in Q2 2013 and has held it in 47 quarters since.
  • Bank of New York Mellon's Altimmune position peaked at $2.16M in Q4 2023.
  • 85 funds tracked by Wall St. Rank held Altimmune as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.